Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study
| Autor: | Marc Sáez-Zafra, Antoni Sicras-Mainar, A. Ruiz-Torrejón, G. Coll-de Tuero, Ruth Navarro-Artieda |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Solifenacin Succinate medicine.medical_specialty Tolterodine Tartrate 030232 urology & nephrology Muscarinic Antagonists Medication Adherence 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Fesoterodine Humans 030212 general & internal medicine Benzhydryl Compounds Retrospective Studies Solifenacin Primary Health Care Urinary Bladder Overactive business.industry Retrospective cohort study General Medicine Middle Aged medicine.disease Overactive bladder Concomitant Anesthesia Female Tolterodine business medicine.drug |
| Zdroj: | Actas Urológicas Españolas (English Edition). 40:96-101 |
| ISSN: | 2173-5786 |
| DOI: | 10.1016/j.acuroe.2015.09.008 |
| Popis: | Objective To assess therapeutic persistence and its relationship with concomitant medication in patients treated with fesoterodine versus tolterodine and solifenacin for overactive bladder (OAB) in standard clinical practice conditions. Material and methods An observational, multicentre retrospective study was performed based on medical registries of patients followed-up in primary care (PC). Three study groups were analyzed. Persistence was defined as the time (in months) without withdrawing from the initial therapy or without changing to another medication for at least 30 days after the initial prescription. The concomitant medications were antidepressants, anxiolytic/hypnotic agents, antibiotics, antiseptic agents, laxatives and skin products. We employed the SPSSWIN program version 17 (statistical significance, p Results We selected 3094 patients for the study. The median age was 54.0 years and 62.2% were women. The patients treated with fesoterodine shown greater treatment persistence (12 months) when compared with those who took solifenacin and tolterodine (40.2% vs. 34.7% and 33.6%, respectively; p = .008). They also showed a lower use of concomitant medication (1.1 vs. 1.2 and 1.2 drugs, respectively; percentages: 61.6% vs. 67.1% and 70.1%, respectively; p Conclusions The patients undergoing OAB treatment with fesoterodine, when compared with those taking solifenacin and tolterodine, were associated with greater treatment persistence and a reduced use of concomitant medication. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect